Inventor · disambiguated record
Tony P. Tang
Also filed as: TANG TONY · TANG TONY P · TANG TONY PISAL
40 granted patents·14 pending applications·292 citations·filing 2005–2024
97Inventor score
Files withARRAY BIOPHARMA INC25MIRATI THERAPEUTICS INC16LILLY CO ELI5LOXO ONCOLOGY INC3BANKA ANNA L2
Top patents by PatentIndex Score
54 records- 0198US10112942B2Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitorsARRAY BIOPHARMA INC·Filed 2017·Granted Oct 30, 2018·29 cites·30 claims
- 0297US10953005B1Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitorsARRAY BIOPHARMA INC·Filed 2020·Granted Mar 23, 2021·4 cites·16 claims
- 0397US10137124B2Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitorsARRAY BIOPHARMA INC·Filed 2018·Granted Nov 27, 2018·12 cites·29 claims
- 0496US11453683B1KRas G12D inhibitorsMIRATI THERAPEUTICS INC·Filed 2020·Granted Sep 27, 2022·13 cites·84 claims
- 0596US10208024B22-aryl- and 2-heteroaryl-substituted 2-pyridazin-3(2H)-one compounds as inhibitors of FGFR tyrosine kinasesARRAY BIOPHARMA INC·Filed 2016·Granted Feb 19, 2019·32 cites·27 claims
- 0696US10172851B2Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitorsARRAY BIOPHARMA INC·Filed 2018·Granted Jan 8, 2019·8 cites·29 claims
- 0796US10125134B2KRas G12C inhibitorsMIRATI THERAPEUTICS INC·Filed 2017·Granted Nov 13, 2018·43 cites·9 claims
- 0894US10555944B2Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitorsARRAY BIOPHARMA INC·Filed 2018·Granted Feb 11, 2020·10 cites·12 claims
- 0993US10633381B2KRas G12C inhibitorsMIRATI THERAPEUTICS INC·Filed 2018·Granted Apr 28, 2020·8 cites·7 claims
- 1093US8324221B2Pyrimidyl cyclopentanes as Akt protein kinase inhibitorsBANKA ANNA L·Filed 2009·Granted Dec 4, 2012·54 cites·60 claims
- 1192US11964989B2KRas G12D inhibitorsMIRATI THERAPEUTICS INC·Filed 2022·Granted Apr 23, 2024·2 cites·19 claims
- 1292US10584124B2Crystalline formsARRAY BIOPHARMA INC·Filed 2018·Granted Mar 10, 2020·12 cites·9 claims
- 1391US11267812B2KRAS G12C inhibitorsMIRATI THERAPEUTICS INC·Filed 2017·Granted Mar 8, 2022·11 cites·34 claims
- 1491US10647715B2KRas G12C inhibitorsMIRATI THERAPEUTICS INC·Filed 2019·Granted May 12, 2020·10 cites·9 claims
- 1591US10172845B2Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitorsARRAY BIOPHARMA INC·Filed 2018·Granted Jan 8, 2019·4 cites·29 claims
- 1689US10730880B24,6-substituted-pyrazolo[1,5-a]pyrazines as Janus kinase inhibitorsARRAY BIOPHARMA INC·Filed 2018·Granted Aug 4, 2020·4 cites·25 claims
- 1789US10144734B2Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitorsARRAY BIOPHARMA INC·Filed 2017·Granted Dec 4, 2018·6 cites·30 claims
- 1888US10441581B2Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitorsARRAY BIOPHARMA INC·Filed 2018·Granted Oct 15, 2019·2 cites·29 claims
- 1987US11998545B2Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitorsARRAY BIOPHARMA INC·Filed 2023·Granted Jun 4, 2024·0 cites·14 claims
- 2087US8329709B25H-cyclopenta[D]pyrimidines as AKT protein kinase inhibitorsBANKA ANNA L·Filed 2009·Granted Dec 11, 2012·10 cites·33 claims
- 2185US9763942B2Serine/threonine kinase inhibitorsARRAY BIOPHARMA INC·Filed 2016·Granted Sep 19, 2017·5 cites·18 claims
- 2284US10745419B2Process for the preparation of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrileLOXO ONCOLOGY INC·Filed 2018·Granted Aug 18, 2020·2 cites·19 claims
- 2382US10881652B2Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitorsARRAY BIOPHARMA INC·Filed 2019·Granted Jan 5, 2021·2 cites·14 claims
- 2482US10154995B2Serine/threonine kinase inhibitorsARRAY BIOPHARMA INC·Filed 2017·Granted Dec 18, 2018·3 cites·18 claims
- 2582US2024101553A1Kras g12c inhibitorsMIRATI THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2681US11932633B2KRas G12C inhibitorsMIRATI THERAPEUTICS INC·Filed 2019·Granted Mar 19, 2024·2 cites·41 claims
- 2781US11098064B2Process for the preparation of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbontrileLOXO ONCOLOGY INC·Filed 2020·Granted Aug 24, 2021·1 cites·9 claims
- 2880US2023090520A1Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitorsARRAY BIOPHARMA INC·Filed 2021·Application pending·0 cites
- 2978US10189845B24,6-substituted-pyrazolo[1,5-a]pyrazines as janus kinase inhibitorsARRAY BIOPHARMA INC·Filed 2015·Granted Jan 29, 2019·2 cites·20 claims
- 3078US2023373999A1Kras g12c inhibitorsMIRATI THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 3177US2024309020A1Kras g12d inhibitorsMIRATI THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 3276US2021186959A1Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitorsARRAY BIOPHARMA INC·Filed 2021·Application pending·0 cites
- 3372US11648243B2Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitorsARRAY BIOPHARMA INC·Filed 2020·Granted May 16, 2023·0 cites·20 claims
- 3471US8895566B25H-cyclopenta[d]pyrimidines as AKT protein kinase inhibitorsARRAY BIOPHARMA INC·Filed 2012·Granted Nov 25, 2014·1 cites·34 claims
- 3569US11807651B2Process for the preparation of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrileLOXO ONCOLOGY INC·Filed 2021·Granted Nov 7, 2023·0 cites·11 claims
- 3668US2020262837A1Kras g12c inhibitorsMIRATI THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 3767US7816523B2Potentiators of glutamate receptorsLILLY CO ELI·Filed 2009·Granted Oct 19, 2010·0 cites·18 claims
- 3866US7803938B2Potentiators of glutamate receptorsLILLY CO ELI·Filed 2009·Granted Sep 28, 2010·0 cites·15 claims
- 3965US10766881B22-aryl- and 2-heteroaryl-substituted 2-pyridazin-3(2H)-one compounds as inhibitors of FGFR tyrosine kinasesARRAY BIOPHARMA INC·Filed 2019·Granted Sep 8, 2020·0 cites·21 claims
- 4064US11028093B24,6-substituted-pyrazolo[1,5-a]pyrazines as janus kinase inhibitorsARRAY BIOPHARMA INC·Filed 2020·Granted Jun 8, 2021·0 cites·19 claims
- 4162US9328091B25H-cyclopenta[d]pyrimidines as AKT protein kinase inhibitorsARRAY BIOPHARMA INC·Filed 2014·Granted May 3, 2016·0 cites·3 claims
- 4259US2020308170A1Kras g12c inhibitorsMIRATI THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 4358US7858646B2Potentiators of glutamate receptorsLILLY CO ELI·Filed 2005·Granted Dec 28, 2010·0 cites·23 claims
- 4458US7678794B2Potentiators of glutamate receptorsLILLY CO ELI·Filed 2005·Granted Mar 16, 2010·0 cites·19 claims
- 4557US7598423B2Potentiators of glutamate receptorsLILLY CO ELI·Filed 2005·Granted Oct 6, 2009·0 cites·23 claims
- 4657US2024034733A1Kras g12d inhibitorsMIRATI THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 4755US2023357277A1Kras g12d inhibitorsMIRATI THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 4854US2023339976A1Kras g12d inhibitorsMIRATI THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 4953US2023279025A1Kras g12d inhibitorsMIRATI THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 5051US9346805B2Pyrimidyl cyclopentanes as Akt protein kinase inhibitorsARRAY BIOPHARMA INC·Filed 2012·Granted May 24, 2016·0 cites·59 claims
Showing the top 50 of 54 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Tony P. Tang files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →